Christine Crute

Christine Crute

Auto-generated profile, based on publicly available information

Christine Crute

Health and Environmental Sciences Institute , Washington, DC 20005

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Toxicological Sciences
Verified
Journal Article
Open access
DRDavid Rouquié
David Rouquié
ABAndreas Bender
Andreas Bender
JCJaime Cheah
Jaime Cheah
CCChristine E Crute
Christine E Crute
DDDeidre Dalmas
Deidre Dalmas
ACAnne E Carpenter
Anne E Carpenter
Next Generation Risk Assessment (NGRA) aims to improve safety testing of pharmaceuticals, agrochemicals, and industrial chemicals. NGRA employs new approach methodologies, such as novel in vitro assays coupled with exposure modeling, to minimize the use of animal models, which can fail to predict specific biological effects in humans. The strategy of the ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium combines multi-omics technologies (including transcriptomics, proteomics, and Cell Painting [high-content imaging]) and multiple cell model systems (ranging from simple cell cultures to complex organotypic models). By integrating these approaches with internal exposure estimates, the consortium aims to improve the translation between in vitro and in vivo test systems, ultimately enhancing the relevance of safety assessment to human biology. OASIS’s integrated approach aims to better translate the biological effects across different chemical and biological spaces, starting with the liver as a use case. By using compounds with well-characterized in vivo and in vitro nonclinical safety and toxicology data related to adverse organ-specific effects in rats and humans, OASIS aims to create novel integrated methods that improve safety assessment while reducing animal use. Ideally, these efforts will contribute to regulatory science across sectors and support the adoption of more predictive, efficient, and cost-effective toxicological models.

25 August 2025 in Toxicological Sciences
Verified
Journal Article
Open access
CMConstance Mitchell
Constance Mitchell
LWLeah Wehmas
Leah Wehmas
DRDavid Rouquié
David Rouquié
FCFlorian Caiment
Florian Caiment
RCRichard A Currie
Richard A Currie
CCChristine E Crute
Christine E Crute
Toxicology is shifting toward predictive, mechanism-based approaches that support quicker, more human-relevant risk assessments and reduce reliance on animal testing. Central to this shift are short-term in vivo studies enriched with omics endpoints, which provide early molecular indicators of toxicity. These data enable the derivation of molecular points of departure and other biologically anchored metrics that can inform potency ranking, hazard identification, and risk assessment. This commentary summarizes insights from the 2025 Society of Toxicology session of the same name and highlights the importance of aligning technical advances with regulatory needs. Next-Generation Risk Assessment (NGRA) is a safety evaluation approach that incorporates emerging tools such as in vitro methods, computational models, and omics data to inform decision-making for human health and the environment, while aiming to reduce dependence on traditional animal testing. NGRA frameworks, while potentially generic in principle, must be tailored to the specific regulatory requirements and exposure contexts of different product sectors, including pharmaceuticals, industrial chemicals, agrochemicals, and cosmetics. Short-term mechanistic animal studies serve as a bridge between traditional long-term animal testing and new approach methodologies. From a technical standpoint, the generation, analysis, and interpretation of omics data have matured considerably, bringing regulatory acceptance within reach. Remaining challenges include standardizing bioinformatics pipelines, building confidence through validation against apical endpoints, and expanding training. Addressing these gaps through collaborative science and flexible regulatory frameworks will be key to realizing the full potential of omics-enabled hazard profiles to support NGRA.

28 August 2025 in Toxicology
Verified
Journal Article
Closed access
JHJulia Happel
Julia Happel
NMNamya Mellouk
Namya Mellouk
CCChristine Crute
Christine Crute
LFLiping Feng
Liping Feng

1 October 2025 in Toxicological Sciences
Verified
Journal Article
Open access
XWXiaotong Wang
Xiaotong Wang
CCChristine E Crute
Christine E Crute
AAAshley Allemang
Ashley Allemang
JAJiri Aubrecht
Jiri Aubrecht
FBFlorence Burleson
Florence Burleson
HLHeng-Hong Li
Heng-Hong Li
Standard in vitro genotoxicity assays often suffer from low specificity, leading to irrelevant positive findings that require costly in vivo follow-up studies. The TGx-DDI (Toxicogenomic DNA Damage-Inducing) transcriptomic biomarker was developed to address this limitation by identifying DNA damage-inducing compounds through gene expression profiling in human TK6 lymphoblastoid cells. To qualify TGx-DDI as a reliable, reproducible biomarker for augmenting genotoxicity hazard assessment, a multi-site ring-trial was conducted across four laboratories using 14 blinded test compounds and standardized protocols. TK6 cells were exposed to three concentrations of each compound, followed by RNA extraction and digital nucleic acid counting using the NanoString nCounter platform. A three-pronged bioinformatics approach—Nearest Shrunken Centroid Probability Analysis, Principal Component Analysis, and Hierarchical Clustering—was used to assign DDI or non-DDI classifications. TGx-DDI demonstrated 100% sensitivity, 86% specificity, and 91% accuracy in distinguishing DDI from non-DDI compounds under validated test conditions. High interlaboratory concordance was observed (agreement coefficients ≥0.61), and transcriptomic data showed strong cross-site correlation (Pearson r > 0.84). The biomarker reproducibly classified test agents even when conducted across study sites. These results demonstrate that TGx-DDI is a robust and reproducible transcriptomic biomarker that enhances the specificity of genotoxicity testing by distinguishing biologically relevant DNA damage responses. Its integration into genotoxicity testing strategies can support regulatory decision-making, reduce unnecessary animal use, and improve the assessment of human health risks.

1 October 2026 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Open access
AWAndrew Williams
Andrew Williams
JBJulie K. Buick
Julie K. Buick
JAJiri Aubrecht
Jiri Aubrecht
FBFlorence Burleson
Florence Burleson
CCChristine E. Crute
Christine E. Crute
CYCarole L. Yauk
Carole L. Yauk
TGx‐DDI and TGx‐HDACi are transcriptomic biomarkers used to classify chemicals based on gene expression profiles indicative of DNA damage‐inducing (DDI) or histone deacetylase inhibition (HDACi) mechanisms. Both employ nearest shrunken centroid (NSC) analysis, hierarchical cluster analysis (HCA), and principal component analysis (PCA). While NSC allows for inconclusive calls when class membership probability is low, PCA has historically lacked an objectively defined inconclusive region. This study establishes a distance‐based probabilistic threshold for PCA, using TGx‐DDI as the primary example, to define a quantitative inconclusive zone along the first principal component (PC1). Samples with ambiguous PC1 values are objectively classified as inconclusive, preventing overconfident misclassifications of weak transcriptomic signals. For TGx‐HDACi, the inconclusive region is narrower but widens substantially with fewer biomarker genes, highlighting increased uncertainty with limited transcriptomic data. Implementing these thresholds enhances the reliability of TGx‐DDI assessments, transparently aligning PCA with NSC to inform regulatory decision‐making.